NCT_ID,Title,Official_Title,Status,Start_Date,Primary_Completion,Study_Type,Phases,Enrollment,Conditions,Sex,Min_Age,Max_Age,Lead_Sponsor,Brief_Summary,Eligibility,Primary_Measures,Secondary_Measures,Interventions,elig_len,eligibility_json
NCT06400472,A Study of LY4170156 in Participants With Selected Advanced Solid Tumors,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",RECRUITING,2024-05-20,2027-02,INTERVENTIONAL,PHASE1,495,"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms",ALL,18 Years,,Eli Lilly and Company,"The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.","Inclusion Criteria: * Have one of the following solid tumor cancers: * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC) * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC Exclusion Criteria: * Individual with known or suspected uncontrolled central nervous system (CNS) metastases * Individual with history of carcinomatous meningitis * Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection * Individual with evidence of corneal keratopathy or history of corneal transplant * Any serious unresolved toxicities from prior therapy * Significant cardiovascular disease * Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms) * History of pneumonitis/interstitial lung disease * Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156 | Phase 1a: To determine the RP2D or optimal dose of LY4170156 with bevacizumab | Phase 1a: To determine the RP2D or optimal dose of LY4170156 with carboplatin | Phase 1a: To determine the RP2D or optimal dose of LY4170156 with pembrolizumab | Phase 1b: To assess the antitumor activity of LY4170156 Monotherapy: Overall response rate (ORR) | Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,To characterize the pharmacokinetics (PK) properties of LY4170156: Minimum Plasma Concentration (Cmin) | To characterize the PK properties of LY4170156: Cmin with bevacizumab or carboplatin | To characterize the PK properties of LY4170156: Cmin with pembrolizumab | To characterize the PK properties of LY4170156: Area under the concentration versus time curve (AUC) | To evaluate the preliminary antitumor activity of LY4170156: Overall response rate (ORR) | To evaluate the preliminary antitumor activity of LY4170156: Overall response rate (ORR) with bevacizumab or carboplatin or pembrolizumab | To evaluate the preliminary antitumor activity of LY4170156: Duration of response (DOR) | To evaluate the preliminary antitumor activity of LY4170156: Duration of response (DOR) with bevacizumab or carboplatin or pembrolizumab | To evaluate the preliminary antitumor activity of LY4170156: Time to response (TTR) | To evaluate the preliminary antitumor activity of LY4170156: Time to response (TTR) with bevacizumab or carboplatin or pembrolizumab | To evaluate the preliminary antitumor activity of LY4170156: Progression free survival (PFS) | To evaluate the preliminary antitumor activity of LY4170156: Progression free survival (PFS) with bevacizumab or carboplatin or pembrolizumab | To evaluate the preliminary antitumor activity of LY4170156: Disease control rate (DCR) | To evaluate the preliminary antitumor activity of LY4170156: Disease control rate (DCR) with bevacizumab or carboplatin or pembrolizumab,DRUG:LY4170156 | DRUG:bevacizumab | DRUG:carboplatin | DRUG:Itraconazole | DRUG:pembrolizumab,1251,"{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': '', 'histology_subtype': '', 'stage': '', 'stage_list': [], 'metastatic': None, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': None, 'max': None}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': [], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'excluded', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': 470, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': True, 'other_inclusions': ['Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer', 'endometrial cancer', 'cervical cancer', 'non-small cell lung cancer (NSCLC)', 'triple negative breast cancer (TNBC)', 'pancreatic cancer', 'colorectal cancer (CRC)']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': True, 'grade_2_or_higher_neuropathy': None, 'history_of': ['carcinomatous meningitis', 'corneal transplant', 'pneumonitis/interstitial lung disease'], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection', 'Significant cardiovascular disease', 'Serious unresolved toxicities from prior therapy']}}"
NCT01944137,Improving Care After Chemotherapy,Improving Care After Chemotherapy,COMPLETED,2013-09,2014-11,INTERVENTIONAL,NA,120,"Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer",ALL,18 Years,,Massachusetts General Hospital,"The main purpose of this study is to examine changes in patient-reported symptoms during the first two cycles of neoadjuvant or adjuvant chemotherapy for non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer, among patients who receive standard care plus a proactive nursing intervention relative to patients who receive standard care alone. Interventions to improve symptom management and prevent urgent care needs in both the clinic and hospital for patients receiving chemotherapy with curative intent are needed to enhance the quality of cancer care.","Inclusion Criteria: * Adult (age 18 or older) * Newly diagnosed stage I-III colorectal cancer, non-small-cell lung cancer, or breast cancer * Scheduled to receive neoadjuvant chemotherapy (i.e. pre-surgical cancer-directed therapy with curative intent) or adjuvant chemotherapy (i.e. post-surgical cancer-directed therapy with curative intent) * Able to respond to questions in English Exclusion Criteria: * Already received 1 or more cycles of chemotherapy for the current regimen * Unwilling or unable to participate in the study",Change from baseline (i.e. first chemotherapy administration visit) in patient-reported symptoms as measured by the Memorial Symptom Assessment Scale-Short Form.,"Change from baseline (i.e. first chemotherapy administration visit) in patient-reported psychological distress as measured by the Patient Health Questionnaire-4. | Change from baseline (i.e. first chemotherapy administration visit) in patient-reported satisfaction with oncology care as measured by the Family Caregiver Satisfaction-patient scale | Frequency of urgent outpatient Cancer Center visits, emergency department visits, and hospital admissions during six months post-baseline",OTHER:Nursing Intervention,531,"{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'non-small cell lung cancer, breast cancer, colorectal cancer', 'histology_subtype': '', 'stage': 'I-III', 'stage_list': ['I', 'II', 'III'], 'metastatic': False, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': None, 'max': None}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': ['chemotherapy for current regimen'], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': None, 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Scheduled to receive neoadjuvant or adjuvant chemotherapy', 'Able to respond to questions in English']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': None, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': [], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Already received 1 or more cycles of chemotherapy for the current regimen', 'Unwilling or unable to participate in the study']}}"
NCT01780675,Hippocampus Avoidance PCI vs PCI,Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial,COMPLETED,2013-04,2019-04-01,INTERVENTIONAL,PHASE3,168,"Small Cell Lung Cancer, Lung Cancer",ALL,18 Years,,The Netherlands Cancer Institute,"Using Intensity Modulated radiotherapy it is possible to treat the entire brain to standard dosages of whole-brain radiation, while keeping the radiation dose to the hippocampus low. However, a clear relationship between radiation dose and damage to the hippocampal stem cells has not been established yet. This study is initiated to investigate the early and delayed neurotoxicity of PCI and to assess in a randomised design the benefits and risks of sparing the hippocampus in Small Cell Lung Cancer patients who receive PCI.","Inclusion Criteria: * \- Small Cell Lung Cancer patients (stage I-III or stage IV without clinical or radiological evidence of brain metastases) candidate for PCI, i.e. without progressive disease after chemo-radiotherapy in stage I-III or after a remission after chemotherapy in stage IV * Sufficient proficiency in Dutch Exclusion Criteria: * Prior radiotherapy to the brain * Clinical evidence for brain metastases or primary brain tumors- Evidence of progressive extracranial metastatic disease * Previous malignancy \< 2 years ago except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix * Any systemic anticancer treatment during PCI or within 3 weeks before start PCI * Pregnancy or lactation",neurocognitive decline,safety,RADIATION:Radiation Prophylactic Cranial Irradiation | RADIATION:Radiation Hippocampal Avoidance PCI,741,"{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'small cell lung cancer', 'histology_subtype': '', 'stage': 'I-III or stage IV without brain metastases', 'stage_list': ['I', 'II', 'III', 'IV'], 'metastatic': False, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': None, 'max': None}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': ['chemo-radiotherapy in stage I-III or chemotherapy in stage IV'], 'allowed': [], 'disallowed': ['systemic anticancer treatment during PCI or within 3 weeks before start PCI'], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'excluded', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Sufficient proficiency in Dutch']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': ['prior radiotherapy to the brain', 'previous malignancy < 2 years ago except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix'], 'concurrent_medications_disallowed': ['systemic anticancer treatment during PCI'], 'other_exclusions': ['Evidence of progressive extracranial metastatic disease']}}"
NCT05369312,Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients,Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients,UNKNOWN,2022-06,2024-05-01,INTERVENTIONAL,PHASE1,230,"Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer",ALL,18 Years,75 Years,"Betta Pharmaceuticals Co., Ltd.","A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.","Inclusion Criteria: * Signed informed consent; * Age ≥18 and ≤75 years, male and female patients; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; * Dose escalation phase: histologically or cytologically confirmed locally advanced or metastatic solid tumor patients (excluding HCC patients), who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * Dose expansion phase: histologically or cytologically confirmed locally advanced non-small cell lung cancer, pancreatic cancer, colorectal cancer or other diagnosed solid tumor patients (excluding HCC patients), who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * Evaluable lesion required for dose escalation phase and at least 1 measurable lesion as per RECIST v1.1 required for dose expansion phase; * Dose expansion only: Patients must have confirmation of tumour mutation status (including KRAS G12, Class-3 BRAF, NF1 LOF mutations, RTK mutations, amplifications or rearrangements). * Adequate organ function; Exclusion Criteria: * Patients who have previously received a SHP2 inhibitor; * Inadequate wash-out of prior therapies described per protocol, which may include anti-tumor therapies, tumor adjuvant drugs, organ or stem cell transplantation, moderate or strong CYP3A inhibitor or inducer; * Patients with severe or unstable systemic disease, unstable/symptomatic CNS metastasis, other malignant tumors, autoimmune disease, ILD, cardiac disease, bleeding or embolic disease, infectious disease, conditions affecting drug swallow and absorption, medical history leading to chronic diarrhea, etc; * Pregnancy or lactation; * Other conditions considered not appropriate to participate in this trial by the investigators.",The adverse events (AEs) | Determine the recommended Phase II dose (RP2D),Cmax | Tmax | t1/2 | AUC0-t | the objective response rate (ORR） | Disease control rate (DCR） | Duration of response (DOR） | Progression free survival (PFS),DRUG:BPI-442096,1902,"{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': 75}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': 'histology or cytology', 'cancer_type': '', 'histology_subtype': '', 'stage': 'locally advanced or metastatic', 'stage_list': [], 'metastatic': True, 'measurable_disease_recist': True, 'biomarker_required': ['KRAS G12', 'Class-3 BRAF', 'NF1 LOF mutations', 'RTK mutations', 'amplifications or rearrangements']}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 1}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': ['SHP2 inhibitor'], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'excluded', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Evaluable lesion required for dose escalation phase', 'At least 1 measurable lesion as per RECIST v1.1 required for dose expansion phase', 'Adequate organ function']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': True, 'grade_2_or_higher_neuropathy': None, 'history_of': ['other malignant tumors', 'autoimmune disease', 'ILD', 'cardiac disease', 'bleeding or embolic disease', 'infectious disease', 'chronic diarrhea'], 'concurrent_medications_disallowed': ['moderate or strong CYP3A inhibitor or inducer'], 'other_exclusions': ['Inadequate wash-out of prior therapies', 'Severe or unstable systemic disease', 'Conditions affecting drug swallow and absorption']}}"
NCT07106528,Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer,"Organoid-Based Drug Sensitivity Model Guided Personalized Precision Treatment for Extensive-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Randomized Controlled Trial",NOT_YET_RECRUITING,2025-08,2027-12,INTERVENTIONAL,"PHASE2, PHASE3",128,"Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Small Cell Lung Cancer ( SCLC )",ALL,18 Years,,Peking Union Medical College Hospital,"This study aims to provide personalized treatment options for patients with extensive-stage small cell lung cancer (SCLC) whose disease has worsened after initial chemotherapy. Researchers will use a novel approach called ""tumor organoid drug sensitivity testing"": A small sample of the patient's tumor (from biopsy or fluid) is grown into miniature 3D tumor models (""organoids"") in the lab. These organoids are exposed to various FDA-approved second-line drugs (including chemotherapy and newer targeted/immunotherapy drugs if available). The most effective drug for each patient's organoids will be recommended for their treatment. 128 participants will be randomly assigned to one of two groups:Experimental Group: Receive organoid-guided personalized therapy; Control Group: Receive standard second-line chemotherapy (Topotecan). The study will compare: How long the cancer remains controlled (Progression-Free Survival); Overall survival time; Treatment response rates and side effects. Potential benefits: May identify more effective treatments for individual patients; Could extend time without cancer progression. Risks: Organoid testing requires an additional tumor biopsy/fluid collection; Possible side effects from second-line drugs.","Inclusion Criteria: 1. Aged 18 years or older. 2. Pathologically confirmed extensive-stage small cell lung cancer (ES-SCLC) (AJCC 9th edition, Stage IV). 3. Previously received first-line platinum-based systemic chemotherapy and experienced recurrence or progression during first-line treatment or within ≤ 6 months after completion of first-line treatment. 4. Availability of sufficient tumor tissue or malignant serous effusion for organoid culture. 5. Presence of measurable lesions based on RECIST 1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Adequate bone marrow and organ function, confirmed by baseline blood count, blood biochemistry, and urine biochemistry tests. 8. Asymptomatic and stable central nervous system (CNS) metastases are allowed. 9. Expected survival of at least 3 months. 10. For male participants: Agreement to use effective contraception during treatment and for at least 180 days after the last dose of study treatment; prohibition of sperm donation during this period. 11. For female participants: Not pregnant or breastfeeding, and meeting at least one of the following: Women of non-childbearing potential; or Agreement to use effective contraception during treatment and for at least 180 days after the last dose of study treatment; or Women of childbearing potential must have a negative serum or urine pregnancy test (with a minimum sensitivity of 25 IU/L or HCG equivalent units) within 72 hours before initiating treatment. 12. Voluntary participation with signed informed consent and willingness to comply with study follow-up procedures. Exclusion Criteria: 1. Mixed tumor pathology or lack of histological confirmation. 2. Previous receipt of second-line or higher systemic anti-tumor therapy for ES-SCLC. 3. Symptomatic or progressive brain metastases, or meningeal metastases. 4. History of other malignant tumors that are progressive or require active treatment within the past 5 years. 5. Presence of active infections, severe organ dysfunction, or other contraindications to anti-tumor treatment. 6. Inability to obtain tumor tissue or insufficient malignant serous effusion for collection. 7. Expected survival of less than 3 months. 8. Inability to complete standardized clinical diagnosis/treatment or regular follow-up.",Progression-Free Survival (PFS),Overall Survival (OS) | Objective Response Rate (ORR) | Duration of Response (DOR) | Grade ≥3 Adverse Events,DRUG:Organoid Drug Sensitivity Testing-Guided Therapy | DRUG:Topotecan,2304,"{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': 'pathology', 'cancer_type': 'small cell lung cancer', 'histology_subtype': 'extensive-stage', 'stage': 'Stage IV', 'stage_list': ['Stage IV'], 'metastatic': None, 'measurable_disease_recist': True, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 1}, 'life_expectancy_weeks': 12, 'prior_therapy': {'required': ['first-line platinum-based systemic chemotherapy'], 'allowed': [], 'disallowed': ['second-line or higher systemic anti-tumor therapy'], 'max_lines_systemic': 1, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'allowed_if_asymptomatic_and_stable', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': True, 'other_inclusions': ['Sufficient tumor tissue or malignant serous effusion for organoid culture', 'Adequate bone marrow and organ function']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': True, 'grade_2_or_higher_neuropathy': None, 'history_of': ['other malignant tumors within the past 5 years'], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Mixed tumor pathology or lack of histological confirmation', 'Active infections', 'Severe organ dysfunction', 'Inability to complete standardized clinical diagnosis/treatment or regular follow-up']}}"
